Insider Buying: Hyperion DeFi (NASDAQ:HYPD) CFO Purchases $100,340.50 in Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD) CFO David Knox bought 27,950 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was bought at an average price of $3.59 per share, for a total transaction of $100,340.50. Following the purchase, the chief financial officer owned 327,950 shares in the company, valued at approximately $1,177,340.50. This represents a 9.32% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Hyperion DeFi Stock Down 7.5%

NASDAQ:HYPD opened at $3.56 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The company has a market capitalization of $29.09 million, a price-to-earnings ratio of -0.88 and a beta of 2.69. Hyperion DeFi, Inc. has a one year low of $0.85 and a one year high of $17.18. The stock has a 50-day simple moving average of $4.30 and a 200 day simple moving average of $7.54.

Hyperion DeFi (NASDAQ:HYPD) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $0.36 million for the quarter. Sell-side analysts predict that Hyperion DeFi, Inc. will post -41.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HYPD has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Chardan Capital set a $7.75 target price on shares of Hyperion DeFi and gave the stock a “buy” rating in a report on Wednesday, December 24th. Zacks Research upgraded shares of Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Wall Street Zen raised shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Cantor Fitzgerald assumed coverage on shares of Hyperion DeFi in a research note on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Hyperion DeFi presently has an average rating of “Hold” and a consensus target price of $4.58.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.